Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

Scitop Bio-tech’s KEX02 Live Bacteria Therapy Gets FDA IND Approval for NSCLC

Fineline Cube Aug 23, 2022

Beijing Scitop Bio-tech Co., Ltd (SHE: 300858) announced that the US Food and Drug Administration...

Company Deals

Sanyou Biopharmaceuticals and KangaBio Ink Licensing Deal for Antibody Drug Candidate

Fineline Cube Aug 22, 2022

Shanghai-based Sanyou Biopharmaceuticals Co., Ltd and KangaBio have entered into a licensing agreement, granting Kanga...

Company

InnoCare Pharma’s 2022 Interim Report Shows Strong Revenue Growth Driven by Orelabrutinib Sales

Fineline Cube Aug 22, 2022

China-based InnoCare Pharma (HKG: 9969) announced its 2022 interim financial results, reporting total revenues of...

Company Deals

Porton Biologics Completes RMB 520M Series B to Expand Gene and Cell Therapy CDMO Platform

Fineline Cube Aug 22, 2022

Suzhou Porton Biologics Ltd, a China-based contract development and manufacturing organization (CDMO), announced the completion...

Company Drug

Nuance Pharma Gets NMPA Green Light for Ensifentrine COPD Trials in China

Fineline Cube Aug 22, 2022

China-based Nuance Pharma has secured approval from the National Medical Products Administration (NMPA) to conduct...

Company

Lundbeck’s Vyepti Fails to Accelerate China Launch via SUNLIGHT Trial

Fineline Cube Aug 22, 2022

Lundbeck’s attempt to fast-track migraine drug Vyepti (eptinezumab) into China and Asia via the SUNLIGHT...

Company

Mindray Bio-Medical’s H1 2022 Revenues Jump 20.17% to RMB 15.3B

Fineline Cube Aug 22, 2022

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) reported robust financial results for H1 2022,...

Company Deals

JJET Raises RMB 700M in Series A+ and B Rounds for Cardiac Electrophysiology Products

Fineline Cube Aug 22, 2022

JJET, a Chengdu-based specialist in cardiac electrophysiology interventional therapy, has completed Series A+ and Series...

Company Drug

IASO Biotherapeutics’ BCMA CAR-T Therapy Approved for NMOSD in China

Fineline Cube Aug 22, 2022

China-based IASO Biotherapeutics announced that the National Medical Products Administration (NMPA) has approved its Investigational...

Company

Hengrui Medicine’s H1 2022 Revenues Drop 23% Amid Generic Price Cuts and COVID-19 Disruptions

Fineline Cube Aug 22, 2022

Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) reported a 23.08% year-on-year (YOY) decline in revenues...

Company Drug

Allist Pharmaceuticals Receives NMPA Approval for Furmonertinib in Exon 20 Insertion NSCLC

Fineline Cube Aug 22, 2022

Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Daiichi Sankyo’s Enhertu Accepted for Review in China for HER2-Low Breast Cancer

Fineline Cube Aug 19, 2022

Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced that its market approval filing for Enhertu (T-DXd,...

Policy / Regulatory

NHSA Proposes Regulations to Standardize Oral Implant Charges and Reduce Costs

Fineline Cube Aug 19, 2022

The National Healthcare Security Administration (NHSA) has released a draft proposal titled “Notice on Carrying...

Company Digital

Ping An Good Doctor Reports 2022 Interim Results with Revenue Decline and User Growth

Fineline Cube Aug 19, 2022

China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good...

Company

WuXi STA Breaks Ground on New US Manufacturing Site in Delaware

Fineline Cube Aug 19, 2022

WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced the commencement...

Company Deals

ZhenGe Biotech Secures RMB 100 Million in Series C+ Funding for CDMO Expansion

Fineline Cube Aug 19, 2022

China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has reportedly raised RMB 100 million...

Company Drug

Zhejiang Erying’s Acetaminophen Set for CDE Priority Review in Pediatric Fever and Pain

Fineline Cube Aug 19, 2022

The Center for Drug Evaluation (CDE) has indicated that Zhejiang Erying Pharmaceutical Co., Ltd’s acetaminophen...

Company

Henlius Pharma’s 2022 Interim Revenue Jumps 103.5% on Biosimilar Sales and Licensing

Fineline Cube Aug 19, 2022

Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) reported RMB 1.29 billion (USD 189.4 million) in...

Company Deals

LongBio Pharma Raises Series A+ Funding to Advance Autoimmune Disease Drug Development

Fineline Cube Aug 19, 2022

LongBio Pharma, a Shanghai-based next-generation macromolecular antibody developer, has raised tens of millions of renminbi...

Company Drug

Fosun Kite’s Yescarta CAR-T Therapy Secures New Clinical Trial Approval in China

Fineline Cube Aug 19, 2022

Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd...

Posts pagination

1 … 677 678 679 … 709

Recent updates

  • AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
  • Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA
  • Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China
  • Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors
  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Company Drug

Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China

Company Drug

Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.